Delivery Is Now Written Into the Collaboration
Two July agreements put delivery capability alongside drug discovery or fragrance formulation. Their technologies and end uses differ, but the public terms show what the partners chose to develop together.
Two deals, two different delivery problems
In a July 2 stock-exchange announcement, CSPC Pharmaceutical Group described an agreement with AstraZeneca to use its siRNA discovery and extrahepatic targeted-delivery platforms to develop preclinical candidates for two targets with potential renal-disease applications. Delivery is named in the scope of the research collaboration; the announcement does not report an approved drug or a skin-delivery result. [1]
On July 7, Givaudan announced an equity investment and strategic collaboration with Microcaps AG. It plans to combine fragrance formulation expertise with Microcaps’ precision microencapsulation technology, especially for non-alcoholic fine fragrance performance and possible beauty applications. The release describes an intended collaboration, not a jointly validated product. [2]
Read the terms before the headline number
CSPC disclosed a $30 million upfront payment, up to $540 million in potential development milestones, up to $1.2 billion in potential sales milestones, and potential royalties. The milestone amounts are conditional; they are not cash already received. Givaudan’s release does not disclose an investment value. [1, 2]
The useful signal is more specific than a large deal value. One agreement pairs drug discovery with a targeted delivery platform; the other pairs fragrance formulation with encapsulation. Those are different materials, destinations and tests. Neither announcement establishes the performance of a topical skin-delivery system or any N1 Life partnership. For a prospective collaborator, the question is which delivery work is actually in scope—and what evidence the next development stage must produce.